To characterize the hydrolysis of the peptide prodrug pomaglumetad methionil (LY2140023; (1R,4S,5S,6S)-4-(L-methionylamino)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide), to the active drug LY404039 [(1R,4S,5S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide], a series of in vitro studies were performed in various matrices, including human intestinal, liver, kidney homogenate, and human plasma. The studies were performed to determine the tissue(s) and enzyme(s) responsible for the conversion of the prodrug to the active molecule. This could enable an assessment of the risk for drug interactions, an evaluation of pharmacogenomic implications, as well as the development of a Physiologically Based Pharmacokinetic (PBPK) model for formation of the active drug. Of the matrices examined, hydrolysis of pomaglumetad methionil was observed in intestinal and kidney homogenate preparations and plasma, but not in liver homogenate.
Introduction
Activation of prodrugs is often performed by hydrolytic enzymes, with the promoiety typically being an ester or a phosphoester. The extent of characterization of the enzymes responsible for the hydrolytic cleavage of marketed prodrugs is variable. For example, studies have suggested dabegatran etexilate, a diester prodrug, is sequentially hydrolyzed to its active form through the actions of both carboxylesterase 2 and carboxylesterase 1 (Laizure et al., 2014) . In contrast, the product label for tenofovir disoproxil fumarate is much less informative and simply states the diester prodrug requires initial diester hydrolysis for conversion to tenofovir (Viread, 2001) .
Although there are many examples of marketed ester prodrugs, those containing an amide promoiety are much less common due to the relative stability of the amide bond compared with the ester. Midodrine is an example of a marketed amide prodrug that is deglycinated after administration to yield deglymidodrine, the active form of the drug. The enzymes responsible for the conversion of midodrine to deglymidodrine have not been identified. The determination of a specific enzyme can be difficult and is often not performed when the enzyme(s) responsible are not the well studied traditional xenobiotic metabolizing enzymes (e.g., carboxylesterases) or the prodrug is not designed to be converted by a specific enzyme, such as gludopa, which was designed to be cleaved by renal g-glutamyl transpeptidase (Simplicio et al., 2008) .
The amide bonds of xenobiotics can be hydrolyzed by many peptidases and other hydrolases localized in various tissues, including the intestine, liver, kidney, and blood. Butyrylcholinesterase and acetylcholinesterase in the blood as well as carboxylesterases and paraoxonase in the liver are enzymes commonly associated with the hydrolysis of xenobiotics (Liederer and Borchardt, 2006) , with many of these enzymes, especially carboxylesterases, involved in amide hydrolysis. For peptide xenobiotics, aminopeptidase A (AP-A), aminopeptidase N (AP-N), aminopeptidase P, aminopeptidase W (AP-W), dipeptidyl peptidase IV (DPP-IV), and membrane dipeptidase (DPEP1) are enzymes that could be expected to take part in their metabolism (Howell et al., 1992) . Many, but not all, of these enzymes are metalloproteases and require a divalent cation, such as zinc, calcium, and magnesium, for catalytic activity. Therefore, the studies described were performed with tissue homogenates prepared without added EDTA or protease inhibitors and with heparinized plasma. Peptide analogs have been used in published studies as model substrates to assess the activities of several aminopeptidases, DPEP1, and DPP-IV in various matrices (Howell et al., 1992; Hooper et al., 1994) . These analogs were used as model substrates to examine the amidase activity of the tissue homogenates employed in the present study.
In the present manuscript, a series of in vitro experiments were performed in the human liver, kidney, and intestinal homogenates and plasma to characterize the hydrolysis of pomaglumetad methionil, a methionil prodrug of the potent and selective metabotropic glutamate 2/3 receptor agonist LY404039. The formation of the amine LY404039 occurs via cleavage of the amide bond of pomaglumatad methionil (Fig. 1 ). An understanding of the sites of conversion, characteristics of the enzyme(s) involved, and the potential for the metabolism to be saturated or inhibited could enable the understanding of potential pharmacogenomic implications as well as the development of PBPK models and other In Vitro In Vivo Extrapolation methods to assess the disposition of both the prodrug and the active molecules (Posada M et al., manuscript in preparation) . The experiments described used various inhibitors, expressed enzymes, and enzyme kinetic determinations to characterize the hydrolysis of pomaglumetad methionil. Through these in vitro studies, an enzyme that catalyzes the conversion of pomaglumetad methionil to LY404039 was identified. In addition, these studies provide a template for a rigorous assessment of the hydrolysis of other peptide prodrugs.
Materials and Methods
Pomaglumetad methionil (LY2140023 monohydrate) and LY404039 were obtained as reference standards from Eli Lilly and Company (Indianapolis, IN). Actinonin, amastatin, bestatin, cilastatin, 1,10-phenanthroline, flavin adenine dinucleotide (FAD), peroxidase, amino acid oxidase, glutamate-p-nitroaniline (Glu-pNA), L-alanine-7-amido-4-methylcoumarin trifluoroacetate (Ala-AMC), leucine-7-amido-4-methylcoumarin hydrochloride (Leu-AMC), and glycineproline-7-amido-4-methylcoumarin hydrobromide (Gly-Pro-AMC) were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). Glycine-D-Phenylalanine (Gly-D-Phe) was purchased from Bachem (Bubendorf, Switzerland Incubations with Peptide Substrates. The activities of AP-A, AP-N, AP-W, DPP-IV, and DPEP1 were assessed in human intestinal homogenates using Glu-pNA, Ala-AMC, Leu-AMC, Gly-Pro-AMC, and Gly-D-Phe as substrates, respectively. Peptide analogs were incubated at either 100 or 250 mM in 75 mg/ml human intestinal homogenate in 100 mM Tris-HCl, pH 7.4, containing 4 mM CaCl 2 . Formation of 7-amino-4-methylcoumarin was quantified by fluorescence spectrophotometry at an excitation wavelength of 360 nm and an emission wavelength of 470 nm. Formation of p-nitroaniline was quantified by UV spectrophotometry at a wavelength of 405 nm. DPEP1 activity was determined by quantifying the hydrolysis of Gly-D-Phe using the method described by Heywood and Hooper (1995) . Briefly, a fluorometric assay mixture containing FAD, peroxidase, D-amino acid oxidase, and p-hydroxyphenylacetic acid was prepared and incubated with the sample. The formation of D-Phe was quantified fluorometrically after several enzymatic steps involving D-amino acid oxidase and peroxidase.
Incubation of Pomaglumetad Methionil in Human Plasma. Fresh heparinized human blood from four individual donors was centrifuged to separate plasma from red blood cells. Preliminary experiments showed that pomaglumetad methionil turnover in plasma was linear for up to 60 minutes. For the determination of the kinetic parameters, pomaglumetad methionil was incubated at concentrations ranging from 16 to 2000 mM in plasma from each donor in a 96-well plate for 10 minutes at 37°C in a shaking water bath. Incubations were terminated by transferring an aliquot of plasma to methanol containing an internal standard ([ 13 C] 3 LY404039). Incubation of Pomaglumetad Methionil in Tissue Homogenates and with DPEP1. Protein and time linearity were determined through examination of LY404039 formation rates in each of the matrices. These rates were calculated from incubations of a range of tissue homogenate, DPEP1, and substrate concentrations over a 30-minute time course, ensuring the formation of LY404039 was linear over these times with increasing protein concentration. Conditions were selected within this linear range to ensure accurate determination of kinetic parameters and are described in the following paragraph.
For the determination of the kinetic parameters, pomaglumetad methionil was incubated at concentrations ranging from 32 to 4000 mM in all of the matrices examined. The protein concentrations for human intestinal and kidney homogenates were 75 and approximately 300 mg/ml, respectively. Incubations to determine kinetic parameters with DPEP1 were performed at a protein concentration of 50 ng/ml. Each of the matrices was diluted in 100 mM Tris-HCl, pH 7.4, containing 4 mM CaCl 2 . Incubations were performed at 37°C in a shaking water bath for up to 30 minutes depending on the matrix. All incubations were terminated by transferring an aliquot of each incubation to methanol containing an internal standard ([
C] 3 LY404039).
Incubations with Peptidase Inhibitors. Actinonin, amastatin, bestatin, cilastatin, and sitagliptin at a concentration of 100 mM and phenanthroline at a concentration of 1 mM were incubated with 500 mM pomaglumetad methionil in each of the matrices at the protein concentrations described previously for the determination of kinetic parameters. These inhibitors and the concentrations used were chosen from a published study, which examined the metabolism of aspartame (Hooper et al., 1994) . For the IC 50 determination, 50 ng/ml recombinant DPEP1 was incubated with concentrations of cilastatin ranging from 0.05 to 100 mM. Each matrix was preincubated with an inhibitor at least 15 minutes prior to the addition of the substrate. Incubations were terminated by transferring an aliquot of each incubation to methanol containing an internal standard ([ 13 C] 3 LY404039). Sample Preparation and Analysis. Samples were centrifuged to remove the precipitated protein, and the formation of LY404039 was quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS) via direct injection of the resulting supernatants. The analyses were performed in the positive ion mode using selected reaction monitoring [M+H] + transitions m/z 236.1 . 80.1 and m/z 239.1 . 192.1 for LY404039 and [ 13 C] 3 LY404039, respectively. The analytes were chromatographically separated using a Thermo Hypersil SAX 5 mm 30 Â 2.1 mm, analytical column Thermo Scientific (Waltham, MA) and a gradient LC system composed of methanol (mobile phase A) and acetic acid/water (1:1, v/v) (mobile phase B). The gradient profile changed from 2% B at 0 minutes, 25% B at 0.01-0.20 minutes, 75% B at 0.30-0.40 minutes, and 98% at 0.41-0.8 minutes at a flow rate of 1.5 ml/min. Chromatography was performed at ambient laboratory conditions, and the flow was directed to the MS/MS instrument between 0.2 and 0.6 minutes and to waste at all other times.
Standard curve concentrations were study dependent and ranged from 0.049 to 200 mM, with each curve including a minimum of six concentrations of LY404039. In addition, each batch included quality control samples at several concentrations within the standard curve range. The percentage CV and percentage accuracy values for the standard curves ranged from 0.2 to 17.8 and 78.6 to 123.0, respectively. The percentage CV and percentage accuracy values for the quality control samples ranged from 0.6 to 15.5 and 78.2 to 123.2, respectively.
Data Analysis. Mass calibration, data acquisition, chromatographic analysis, mass spectral representation, and postacquisition quantitative analysis were performed via Analyst software version 1.4.2 (Sciex, Foster City, CA). 
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Calculations. Concentration data were processed in Excel 2007 (version 12; Microsoft, Redmond, WA). Kinetic parameters were calculated using XLfit (version 5.3; ID Business Solutions Limited, Guildford, United Kingdom), and the data were best fit to the one-enzyme Michaelis-Menten model. Intestinal and kidney clearance was scaled using the equation V max /K m * homogenate (mg)/tissue (g) * tissue (g)/body weight (kg) * 70 kg. Homogenate (mg)/tissue (g) values were provided by Celsis/In Vitro Technologies for each lot. Factors of 30 and 4.4 g tissue/kg body weight for the intestine and kidney, respectively, were taken from Yamanaka et al. (2007) . The scaled intrinsic clearance values for the plasma were calculated using the equation V max /K m * 3 liters of plasma (Guyton, 1991) . Inhibition data were fit to the four parameter Hill-Slope model using XLfit to determine an IC 50 value.
Results
The hydrolysis of pomaglumetad methionil to LY404039 was examined in vitro in human plasma and homogenates of the human intestine, liver, and kidney. LY404039 was formed in human plasma and human intestinal and kidney homogenates, but not in liver homogenate. Incubation conditions were assessed and selected to ensure the rates of formation of LY404039 were linear, with varying time points and protein concentrations (data not shown). The K m and V max values for each of these matrices and each donor are found in Tables 1-3 . These values were consistent with a low-affinity, high-capacity enzyme-catalyzed reaction that occurred at a relatively slow rate. After the application of standard scaling factors (Yamanaka et al., 2007) , intrinsic clearance values suggested that the intestine and kidney were primary tissues that are likely responsible for the hydrolysis of pomaglumetad methionil, with plasma values relatively lower and the liver below the limit of detection (Tables 1-3) .
Further work was focused on characterizing the enzymes involved in the formation of LY404039. Prior to inhibitor studies with pomaglumetad methionil, human intestinal homogenates were characterized for the activity of peptidase enzymes, including AP-A, AP-N, AP-W, DPP-IV, and DPEP1, primarily using peptide analogs linked to either 7-amino-4-methylcoumarin or p-nitroaniline. The notable exception was the utilization of Gly-D-Phe as a substrate for DPEP1. DPEP1 is one of a few enzymes characterized from multicellular organisms known to effectively hydrolyze peptide bonds containing D-amino acids (Yamada and Kera, 1998) . More specifically, DPEP1 catalyzes the hydrolysis of dipeptides with a D-amino acid in the C-terminal position, making Gly-D-Phe a specific substrate for DPEP1 (Heywood and Hooper, 1995; Yamada and Kera, 1998) . Each of the peptidase activities was observed in human intestinal homogenate. Additional studies with peptidase inhibitors (Table 4) and these model peptide substrates provided both further confirmation of the presence of these activities in the intestinal homogenate and the impetus to use the inhibitors to identify enzymes responsible for LY404039 formation (Figs. 2 and 3) . The inhibitors included actinonin, amastatin, bestatin, cilastatin, and sitagliptin. A list of these inhibitors and their common targets is shown in Table 4 (Kozak and Tate, 1982; Campbell et al., 1988; Howell et al., 1992; Hooper et al., 1994) .
Incubations of pomaglumetad methionil in human intestinal and kidney homogenates and plasma with these inhibitors suggested the involvement of DPEP1 in the formation of the active drug. Although partial inhibition was observed with actinonin, bestatin, amastatin and 1,10-phenanthroline, cilastatin essentially completely inhibited the formation of LY404039 in all of the matrices examined (Fig. 4) . Complete inhibition by cilastatin, a selective inhibitor of DPEP1 (Kahan et al., 1983) , led to further investigations with this enzyme. Subsequent incubations that were performed with the human recombinant enzyme confirmed the ability of DPEP1 to catalyze the hydrolysis of pomaglumetad methionil, with a K m (616 6 21 mM; value 6 S.E.) similar to that observed in incubations with all of the other matrices that converted the prodrug (Tables 1-3 ). The concentration rate data also best fit the one-enzyme Michaelis-Menten model, suggesting a single enzyme. However, the possibility of more than one enzyme with similar affinities is possible. Cilastatin was also shown to completely inhibit the formation of the active drug in incubations with the recombinant enzyme (IC 50 0.5 6 0.1 mM; value 6 S.E.). The IC 50 was similar to that observed for the inhibition of D-Phe formation by cilastatin in the human intestinal homogenate using Gly-D-Phe as a substrate (0.68 6 0.02 mM; value 6 S.E.). In addition, the extent of inhibition observed with actinonin, amastatin, bestatin and 1,10-phenanthroline was quite similar across matrices to the inhibition of recombinant DPEP1, providing further evidence for the importance of the dehydropeptidase in the conversion of pomaglumetad methionil (Fig. 4) .
Discussion
Enzymatic hydrolysis, the oxidative cleavage of an amide or ester bond with water by a catalytic protein, is not a well studied pathway in the metabolism of xenobiotics compared with the more common oxidative metabolism found in enzyme systems, such as the cytochromes P450. A report in 2004 that characterized the clearance routes for the top 200 drugs showed that esterases (hydrolytic enzymes) were responsible for the clearance of only about 10% of drugs (Williams et al., 2004) . The characterization of enzymes that catalyze these reactions are often not completed to the same extent as other enzyme systems, such as the cytochromes P450, due to a lack of previous experience with these enzymes and appropriate in vitro tools. The cytochromes P450, for example, have full arrays of recombinant enzymes, specific inhibitors, and specific substrates that are commercially available, enabling rigorous characterization of the involvement of these enzymes in the metabolism of xenobiotics. Also, many of the CYP enzymes have been quantified in various tissues to allow for the scaling of the activities. Hydrolytic enzymes, on the other hand, are limited to a relatively small number of commercially available enzymes, with a relative dearth of specific substrates and inhibitors. Quantification of the enzymes in tissues is also in its relatively early stages. Making the characterization of hydrolysis pathways more difficult, the commercially available tissue fractions also often contain EDTA, PMSF, or both, which are additives that will inhibit many hydrolytic enzymes. Using the small number of available tools, the hydrolysis of pomaglumetad methionil was characterized in human intestinal, kidney, and liver homogenates and plasma. The work presented provides the methodology for studying the hydrolysis of pomaglumetad and other peptide prodrugs. Assay conditions, such as buffer selection, the use of tissue homogenates without added protease inhibitors or EDTA, and the use of heparin instead of EDTA as an anticoagulant for plasma, are important considerations in the study of hydrolytic enzymes because many are metalloproteases. For example, no conversion of pomaglumetad methionil was observed in two lots of human intestinal homogenates in initial incubations performed in a sodium phosphate buffer. However, when the incubations were repeated using Tris buffer, activity was observed. The addition of calcium and magnesium to the incubation increased the rate of conversion of pomaglumated methionil (Fig. 5) . Chelation of calcium by the phosphate ion in the sodium phosphate buffer is the likely explanation for the lack of conversion observed in preliminary studies. The use of phosphate buffers or other buffers that may chelate metal ions could inhibit the activities of these metalloproteases. All results reported in this study were from incubations performed in Tris buffer with added calcium. Calcium was added in excess to ensure the enzyme activity would not be affected by a lack of divalent cations. The effect of the addition of both calcium and magnesium on the formation of LY404039 was investigated, with essentially no difference observed in the rate of formation with each cation (data not shown).
Due to the limited knowledge of the enzymes involved in the formation of LY404039, tissue homogenates were used in these studies instead of subcellular fractions to increase the possibility the enzymes involved would be represented. However, because these were human tissue preparations, the quality and treatment of the tissue, including the time interval between receipt and processing of the tissue, may be critical to the activity of these enzymes and may explain the observed large differences in V max values between donors (Tables 2 and 3 ). In accordance with this concept, the human plasma was freshly prepared and the range in V max values was substantially reduced.
Prior to incubations to establish kinetic parameters for pomaglumetad methionil hydrolysis, linear rate conditions for LY404039 formation were determined for each of the matrices by incubating multiple concentrations of pomaglumetad methionil, with varying protein concentrations of each matrix for increasing periods of time. Results from these initial incubations dmd.aspetjournals.org enabled an appropriate selection of protein concentration and incubation time for each matrix, where a linear rate of LY404039 formation was maintained. These conditions were critical to ensure first-order rate conditions for the determination of the K m and V max of pomaglumetad methionil hydrolysis. The majority of the inhibitors used in these studies were selected from a publication by Hooper et al. (1994) that describes in vitro work characterizing the metabolism of aspartame. Actinonin, amastatin, and bestatin are all naturally produced by actinomycetes and were originally isolated for either their antibacterial or aminopeptidase inhibitory properties (Umezawa et al., 1976; Aoyagi et al., 1978; Chen et al., 2000) . Actinonin is a known inhibitor of several metallo hydrolases and appears to act through its hydroxamate group, which chelates metal ions required for enzymatic activity (Chen et al., 2000) . Amastatin and bestatin inhibit aminopeptidases primarily through slow, tight, and often time-dependent yet reversible binding to the enzymes (Wilkes and Prescott, 1985) . Evidence suggests these inhibitors may act through the formation of a transition-state analog complex with the enzyme (Wilkes and Prescott, 1985) . In addition, amastatin and bestatin may interact with the metal ions required for activity of these enzymes, with spectral shifts for the metallo hydrolase Aeromonas aminopeptidase observed in the presence of these inhibitors (Wilkes and Prescott, 1985) . Cilastatin was specifically designed as an inhibitor of DPEP1 to be dosed with imipenem, an antibiotic whose b-lactam ring is susceptible to cleavage by the dehydropeptidase (Kahan et al., 1983) . Coadministration of cilastatin with imipenem increases the urinary recovery of the antibiotic, which is typically low when imipenem is dosed alone due to extensive metabolism by DPEP1 in the renal brush border (Kahan et al., 1983) . Sitagliptin is a marketed oral antihyperglycemic drug that acts by competitively inhibiting DPP-IV (Green et al., 2006) . Although these Fig. 3 . Characterization of AP-N, AP-W, and DPP-IV activity across four lots of human intestinal homogenate. The activities of AP-N, AP-W, and DPP-IV were assessed using Ala-AMC, Leu-AMC, and Gly-Pro-AMC as substrates, respectively. Each activity was present and varied to a similar degree across lots, with lots PRN and XJR showing a higher activity for each enzyme than lots QQQ and RDS. AP-N was inhibited by actinonin, AP-W was inhibited by amastatin, and DPP-IV was inhibited by sitagliptin, as expected. Fig. 4 . Effect of peptidase inhibitors on LY404039 formation. Actinonin, amastatin, bestatin, cilastatin, and sitagliptin were incubated at a concentration of 100 mM with each matrix. Phenanthroline was incubated at a concentration of 1 mM with each matrix. Human intestinal homogenate, human kidney homogenate, and human recombinant membrane dipeptidase were incubated at 75 mg/ml, 300 mg/ml, and 50 ng/ml, respectively. The concentration of LY2140023 in each incubation was 500 mM. The percentage of inhibition was determined by comparing LY404039 formation in the presence of each inhibitor to the formation observed in a vehicle control for each matrix examined. Human plasma values represent data from an incubation of equal volumes of plasma pooled from four individual donors. Human intestinal homogenate values (6S.E.M.) represent data from an incubation of four separate lots that were each prepared from a single donor. Human kidney homogenate values (6S.E.M.) represent data from an incubation of three separate lots that were each prepared from a single donor. Human DPEP1 values represent data from a single experiment. dmd.aspetjournals.org Downloaded from studies do not preclude the involvement of other enzymes in the catalysis of LY404039 formation, DPEP1 has been demonstrated to catalyze the hydrolysis of pomaglumetad methionil in human intestinal and kidney homogenates and human plasma. The fact that hydrolysis was not observed in liver homogenate suggested that the enzyme involved in the metabolism of the prodrug was not one of the common xenobiotic metabolizing hydrolysis enzymes, such as carboxylesterase 1 and 2 or paraoxonase. The K m values for LY404039 formation in human intestinal homogenate, kidney homogenate, and plasma were similar to the K m value for human recombinant DPEP1-catalyzed formation. In addition, cilastatin was shown to essentially completely inhibit LY404039 formation in all of the matrices examined. Partial inhibition of LY404039 formation was observed in all matrices in incubations with actinonin, amastatin, bestatin, and 1,10-phenanthroline (Fig. 4) . Because several of these inhibitors act through metal ion chelation and DPEP1 has four zinc molecules involved in catalysis, partial inhibition by several inhibitors was not unexpected. Although some differences were observed in the extent of inhibition for a given inhibitor across matrices, in general, the extent of inhibition of recombinant DPEP1 by each inhibitor was similar to that observed in other matrices. These results provide more evidence that DPEP1 is an important enzyme involved in the formation of LY404039. DPEP1, also known as renal dipeptidase or membrane dipeptidase (EC 3.4.13.19) , is a glycosyl phosphatidylinositol anchored cell-surface zinc metalloprotease that has been characterized extensively in the microvillar membranes of the kidney (Littlewood et al., 1989) . The enzyme is known to catalyze the hydrolysis of dipeptides with D-, L-, or dehydro-amino acids at the C-terminus (Liao et al., 2010) . DPEP1 catalyzes the hydrolysis of beta lactam antibiotics, such as imipenem and carbapenem, as well as glutathione and leukotriene D4. Cilastatin was designed as a selective inhibitor of DPEP1 to be coadministered with imipenem, with the intent of improving the pharmacokinetic profile of the drug by inhibiting the DPEP1-catalyzed hydrolysis of its beta lactam ring (Kahan et al., 1983) . Although an unlikely concomitant medication, Primaxin (imipenem/cilastatin) could affect the exposure of pomaglumetad methionil. Further studies would be required to assess the possibility of a drug interaction with Primaxin.
Pomaglumetad methionil was designed to be actively transported by peptide transporter 1 and has been demonstrated through in vitro transport assays to be a substrate of this transporter (Pak YA et al., manuscript in preparation.) . Peptide transporter 1 is known to be located on the cell surface of the enterocyte; however, the interplay between the conversion of the prodrug to the active drug and the transport of the prodrug in the intestine is not understood. Although DPEP1 is located on the apical side of microvillar membranes in the kidney, the location of intestinal DPEP1 is unknown, although evidence in this study suggests it may not only be on the apical side. Results of these in vitro studies, including affinities, metabolism via expressed enzymes, and inhibition, suggest DPEP1 may play a substantial role in the activation to LY404039. Knowledge of the enzyme identity, tissues involved in metabolism, and enzyme kinetics can allow for the development of PBPK models to assess the disposition of prodrugs and active molecules as well as the potential for marketed drugs to inhibit the conversion. In addition, these studies provide a framework for the characterization of peptidase-mediated hydrolysis.
